This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2005;293:27-28.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In an attempt to tighten the reins over control of dietary supplements, the US Food and Drug Administration (FDA) has announced several regulatory initiatives. The actions come following criticism that the government has reacted too slowly to the dangers posed by supplements such as ephedra and androstenedione, both of which were taken off the market earlier this year.

The new initiatives include a regulatory strategy designed to further implement the Dietary Supplement Health and Education Act of 1994 (DSHEA), an open public meeting, and a draft guidance document for industry. Passage of DSHEA allowed dietary supplements—defined by Congress as products that contain ingredients including vitamins, minerals, herbs or other botanicals, amino acids, and substances such as enzymes, organ tissues, glandulars, and metabolites—to be sold over the counter with little oversight unless the FDA could demonstrate a product posed a clear danger to public health.

"With this strategy, . . . [Full Text of this Article]

IDENTIFYING SAFETY CONCERNS